Kevin O’Leary’s Stock Portfolio: 15 Stock Picks for 2025

Page 9 of 14

6. Johnson & Johnson (NYSE:JNJ)

Number of Hedge Fund Holders: 81

Johnson & Johnson (NYSE:JNJ) is a major player in the healthcare industry, with a portfolio that includes pharmaceuticals, Medtech devices, and consumer health products. The company is known for developing drugs to treat a wide range of conditions and diseases, including cancer, diabetes, and HIV/AIDS.

In its recent earnings report, Johnson & Johnson (NYSE:JNJ) announced a sales increase of 5.3% to $22.5 billion, with operational growth of 6.7%. Moreover, JNJ’s full-year sales increased by 4.3% to $88.8 billion, all while the company highlighted significant progress in its R&D pipeline, which includes advances in treatments for diseases like multiple myeloma and lung cancer. J&J’s MedTech division also experienced considerable growth, owing to innovations in cardiovascular and general surgery products. Johnson & Johnson (NYSE:JNJ) has provided guidance for 2025 as well, predicting operational sales growth of 2.5% to 3.5% alongside an adjusted operational EPS increase of 8.7% at the midpoint.

Page 9 of 14